




PRESS RELEASE

SoftOx attracts renowned inhaled antimicrobial expert Dr. Bruce Montgomery to lead Clinical Advisory Board ahead of Phase 2b

Oslo/Copenhagen, 29 September 2026 – SoftOx Solutions AS ("SoftOx"), a clinical-stage pharmaceutical company developing novel anti-infective therapies for respiratory infections, is pleased to announce that one of the most experienced names in inhaled antimicrobial drug development has agreed to lead SoftOx's Clinical Advisory Board (CAB).



Dr. A. Bruce Montgomery
 Chair, Clinical Advisory Board
 SoftOx Solutions

KEY HIGHLIGHTS



Renowned inhaled antimicrobial expert to lead Clinical Advisory Board



Support next stage of clinical development including a planned Phase 2b programme



Proven track record with TOBI® and CAYSTON® in cystic fibrosis



Strengthens SoftOx's clinical development capabilities and international network

Thomas Bjarnsholt, CEO/CSO of SoftOx Solutions, commented:



"Bruce joining SoftOx at this stage is a major strengthening of our clinical development capabilities. Few people have his combination of experience in cystic fibrosis, inhaled antimicrobial therapies, clinical trial design and regulatory development.

As we move from Phase 2a proof-of-concept towards defining the next clinical stage for SIS, it is extremely valuable to have Bruce chairing our Clinical Advisory Board. Together, we will build a world-class group of clinical experts and establish the framework for a Phase 2b programme designed to determine the optimal dose and generate the clinical evidence required for subsequent development.

Importantly, Bruce also brings the perspective of someone who has successfully taken inhaled therapies beyond clinical development, through regulatory approval and into the hands of patients. That experience will be highly valuable as we make decisions today that can shape the longer-term development path for SIS."

Dr. Bruce Montgomery commented:



"I am pleased to join SoftOx as Chair of the Clinical Advisory Board at an important stage in the development of SIS. Chronic pulmonary infections, including those seen in people with cystic fibrosis, remain an area of significant unmet medical need. The prolonged use of antibiotics to suppress chronic airway infections can contribute to the development and selection of antimicrobial resistance, underscoring the need for new and differentiated treatment approaches.

I look forward to working with the SoftOx team and helping to assemble a strong Clinical Advisory Board to advise on the next stage of clinical development. A key focus will be to help define a rigorous Phase 2b dose-ranging programme that can establish the appropriate dose, patient population and clinical endpoints for SIS and provide a solid foundation for subsequent development towards regulatory approval, and ultimately bringing a new treatment option to patients with chronic lung infections."

SoftOx Inhalation Solution (SIS)

A novel inhaled anti-infective therapy for chronic respiratory infections



Proprietary HOCl formulation stabilised with acetic acid



Broad-spectrum anti-infective activity (bacteria, virus and fungi)



Local delivery to the lungs via nebulization



Developed for chronic respiratory infections with high unmet need

Disclaimer: Certain visual elements in this document were created with the assistance of AI.





PRESS RELEASE

ROLE AND MANDATE

As Chair of the SoftOx Clinical Advisory Board, Dr. Montgomery will:

-  Assist SoftOx in identifying and appointing appropriate international experts to the Clinical Advisory Board.
-  Chair regular Clinical Advisory Board meetings, and participate in additional meetings as required.
-  Advise SoftOx on the overall clinical development strategy for SIS.
-  Provide input into the design of the anticipated Phase 2b dose-ranging programme, including patient population, dose selection, treatment duration, endpoints, microbiological assessments and overall trial design.
-  Advise on the positioning of cystic fibrosis and other chronic pulmonary infections within the longer-term SIS development programme.
-  Provide strategic input on interactions with regulatory authorities and preparation for subsequent clinical development stages.
-  Provide ad hoc scientific and clinical advice to SoftOx management by meeting or email where appropriate.

The parties anticipate regular Clinical Advisory Board meetings approximately every two months, supplemented by ad hoc discussions when required.

The appointment is advisory in nature. Dr. Montgomery will not have executive or operational responsibility within SoftOx. Dr. Montgomery will receive remuneration for his services as Chair of the Clinical Advisory Board. The main terms of the agreement have been agreed between Dr. Montgomery and the Company and include a combination of a cash fee and a share compensation.

SoftOx Inhalation Solution (SIS)

A novel inhaled anti-infective therapy for chronic respiratory infections

-  Broad-spectrum anti-infective activity (bacteria, virus and fungi)
-  HOCl stabilized with acetic acid
-  Local delivery to the lungs via nebulization

ABOUT DR. A. BRUCE MONTGOMERY



Dr. A. Bruce Montgomery is a physician, biotechnology executive and entrepreneur with more than 35 years of experience in pulmonary medicine and drug development.

A recurring theme throughout his career has been taking innovative respiratory therapies from clinical development through regulatory approval and into the market.

As Executive Vice President of R&D at PatToGenesis, he led the development of TOBI[®], the first FDA-approved inhaled antibiotic for cystic fibrosis. He subsequently founded and led Ceryst Pharma, which was acquired by Gilead Sciences, and at Gilead successfully led the development of CAYSTON[®] for cystic fibrosis through approval and commercial launch.


Earlier in his career, he co-invented aerosolized pentamidine and was involved in other development programmes that resulted in approved respiratory medicines.

Dr. Montgomery's career combines deep scientific and clinical expertise in inhaled therapies with the practical experience of building organisations and leading programmes that have converted innovative science into medicines used by patients and families living with serious respiratory diseases.

ABOUT SOFTOX INHALATION SOLUTION

SoftOx Inhalation Solution (SIS) is being developed as an inhaled broad-spectrum anti-infective therapy for chronic respiratory infections.

SoftOx is currently conducting its Phase 2a clinical programme in people with cystic fibrosis, with the objective of establishing initial proof-of-concept and informing subsequent clinical development.



**Innovative science.
Targeted solutions.
Transforming care for patients.**

Disclaimer: Certain visual elements in this document were created with the assistance of AI.